PE20231437A1 - Medicamento de combinacion para el control y manejo de la diabetes mellitus tipo 2 - Google Patents

Medicamento de combinacion para el control y manejo de la diabetes mellitus tipo 2

Info

Publication number
PE20231437A1
PE20231437A1 PE2023000819A PE2023000819A PE20231437A1 PE 20231437 A1 PE20231437 A1 PE 20231437A1 PE 2023000819 A PE2023000819 A PE 2023000819A PE 2023000819 A PE2023000819 A PE 2023000819A PE 20231437 A1 PE20231437 A1 PE 20231437A1
Authority
PE
Peru
Prior art keywords
management
type
control
diabetes mellitus
combination medicine
Prior art date
Application number
PE2023000819A
Other languages
English (en)
Inventor
Rubio Paola Yazmin Ollervides
Leon Sixto Serafin Espinoza
Escobar Ernesto Cuahutencos
Canudas Jorge Alejandro Gonzales
Original Assignee
Laboratorios Silanes S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Silanes S A De C V filed Critical Laboratorios Silanes S A De C V
Publication of PE20231437A1 publication Critical patent/PE20231437A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Referido a un medicamento de combinacion de liberacion inmediata, caracterizado porque comprende: (a) una sulfonilurea, (b) un inhibidor de la dipeptidil peptidasa-4 (DPP4) y (c) una biguanida, o una sal farmaceutica de cualquiera de los mismos, en cantidades farmaceuticamente aceptables que se encuentran en el intervalo entre 1-4 mg, 50 mg y 500-1000 mg respectivamente, en combinacion con excipientes y/o vehiculos farmaceuticamente aceptables; en donde la sulfonilurea como por ejemplo glimepirida, un inhibidor de la dipeptidil peptidasa-4 (DPP4) como por ejemplo vildagliptina, y una biguanidina como por ejemplo metformina. En donde dicho medicamento se encuentra en forma solida y se usa para el control y manejo de la diabetes mellitus tipo 2.
PE2023000819A 2020-09-02 2020-09-02 Medicamento de combinacion para el control y manejo de la diabetes mellitus tipo 2 PE20231437A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2020/050030 WO2022050832A1 (es) 2020-09-02 2020-09-02 Medicamento de combinación para el control y manejo de la diabetes mellitus tipo 2

Publications (1)

Publication Number Publication Date
PE20231437A1 true PE20231437A1 (es) 2023-09-14

Family

ID=80491336

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023000819A PE20231437A1 (es) 2020-09-02 2020-09-02 Medicamento de combinacion para el control y manejo de la diabetes mellitus tipo 2

Country Status (11)

Country Link
US (1) US20230310462A1 (es)
EP (1) EP4180045A4 (es)
JP (1) JP2023543393A (es)
KR (1) KR20230074742A (es)
BR (1) BR112023003866A2 (es)
CA (1) CA3191302A1 (es)
CO (1) CO2023004272A2 (es)
DO (1) DOP2023000044A (es)
MX (1) MX2022015333A (es)
PE (1) PE20231437A1 (es)
WO (1) WO2022050832A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200637839A (en) 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
US9056134B2 (en) 2010-07-21 2015-06-16 Nucitec S.A. De C.V. Single daily dosage form for prevention and treatment of metabolic syndrome
MX339374B (es) 2011-04-29 2016-05-13 Inst De Investigación En Química Aplic S A De C V Cocristales ionicos con base en metformina.
US20160151382A1 (en) * 2013-10-08 2016-06-02 Kevin Ray Pickering Cooperative Medication Combination Systems
EP2992876A1 (en) * 2014-09-05 2016-03-09 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of sitagliptin
KR20180002460A (ko) * 2016-06-29 2018-01-08 주식회사 엘지화학 제2형 당뇨병 및 당뇨성 이상지질혈증 치료용 조성물, 키트 및 병용 요법
TW202102208A (zh) * 2019-03-25 2021-01-16 澳大利亞喬治全球健康研究所 低劑量三重組合調配物

Also Published As

Publication number Publication date
WO2022050832A1 (es) 2022-03-10
DOP2023000044A (es) 2023-04-30
KR20230074742A (ko) 2023-05-31
EP4180045A1 (en) 2023-05-17
MX2022015333A (es) 2023-01-11
CO2023004272A2 (es) 2023-06-20
US20230310462A1 (en) 2023-10-05
EP4180045A4 (en) 2024-04-10
JP2023543393A (ja) 2023-10-16
BR112023003866A2 (pt) 2023-04-04
CA3191302A1 (en) 2022-03-10

Similar Documents

Publication Publication Date Title
CO2023000199A2 (es) Péptidos funcionalizados como agentes antivirales
US7393827B2 (en) Pharmaceutical compositions and methods for restoring β-cell mass and function
AR081254A1 (es) Composicion farmaceutica que comprende ave0010 e insulina glargina
CO2023008018A2 (es) Nuevos agentes antivirales derivados de la espiropirrolidina
AR084698A1 (es) Composiciones de liberacion controlada con reducido efecto de alimentos, reducida interaccion entre farmaco y los alimentos
AR049000A1 (es) Formulacion para compresion directa y proceso para la preparacion de una tableta directamente comprimida
AR037407A1 (es) Composiciones farmaceuticas para el tratamiento de la diabetes mellitus de tipo ii
CO2023002852A2 (es) Péptidos funcionalizados como agentes antivirales
AR055628A1 (es) Dipositivos de administracion transdermicas de farmacos que contienen o- desmetilvenlafaxina (odv) o sus sales
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
UY38958A (es) Agonista del receptor glp-1 y uso de este
BR112022022024A2 (pt) Uso de um componente (i) em combinação com um componente (ii), composição farmacêutica, medicamento composto e kit
CO2022003543A2 (es) Formulaciones inyectables de acción prolongada de sales de pamoato de ketamina
PE20231437A1 (es) Medicamento de combinacion para el control y manejo de la diabetes mellitus tipo 2
UY39786A (es) Derivados de Triazolopirimidina y su uso en el Tratamiento de Enfermedades
CO2024002256A2 (es) Formas de dosificación gastrorretentivas de 5-hidroxitriptófano
ES2526359T3 (es) Formulación galénica oral que comprende ketorolaco y vitaminas del complejo B, en la que la vitamina B6 se encuentra en una capa externa separada del resto de principios activos
CO2022014960A2 (es) Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos
CO2022004572A2 (es) Tratamiento de la diabetes mellitus tipo 2
CO2021018031A2 (es) Una composición farmacéutica para la diabetes mellitus
US20130122050A1 (en) Compositions and methods for treating diabetes using lisofylline analogs and islet neogenesis associated peptide
AR053812A1 (es) Utilizacion de rimonabant para la preparacion de medicamentos utiles en la prevencion y el tratamiento de la diabetes de tipo2
CO2023017669A2 (es) Terapia combinada anti-vhc ventajosa
CO2023000523A2 (es) Composiciones farmacéuticas que comprenden venglustat
CO2024002748A2 (es) Profármaco de derivados de pirrolidona como activador de glucocinasa